331 related articles for article (PubMed ID: 26521151)
21. CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia.
Stefani A; Sancesario G; Pierantozzi M; Leone G; Galati S; Hainsworth AH; Diomedi M
J Neurol Sci; 2009 Aug; 283(1-2):109-15. PubMed ID: 19278690
[TBL] [Abstract][Full Text] [Related]
22. Treatment effects of therapeutic cholinesterase inhibitors on visuospatial processing in Alzheimer's disease: a longitudinal functional MRI study.
Thiyagesh SN; Farrow TF; Parks RW; Accosta-Mesa H; Hunter MD; Young C; Wilkinson ID; Woodruff PW
Dement Geriatr Cogn Disord; 2010; 29(2):176-88. PubMed ID: 20215749
[TBL] [Abstract][Full Text] [Related]
23. Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease.
Leeuwis AE; Benedictus MR; Kuijer JPA; Binnewijzend MAA; Hooghiemstra AM; Verfaillie SCJ; Koene T; Scheltens P; Barkhof F; Prins ND; van der Flier WM
Alzheimers Dement; 2017 May; 13(5):531-540. PubMed ID: 27693109
[TBL] [Abstract][Full Text] [Related]
24. Cerebral blood flow measured by arterial spin labeling MRI at resting state in normal aging and Alzheimer's disease.
Zhang N; Gordon ML; Goldberg TE
Neurosci Biobehav Rev; 2017 Jan; 72():168-175. PubMed ID: 27908711
[TBL] [Abstract][Full Text] [Related]
25. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
Wattmo C; Minthon L; Wallin ÅK
Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
[TBL] [Abstract][Full Text] [Related]
26. Impaired cerebral blood flow in type 2 diabetes mellitus - A comparative study with subjective cognitive decline, vascular dementia and Alzheimer's disease subjects.
Chau ACM; Cheung EYW; Chan KH; Chow WS; Shea YF; Chiu PKC; Mak HKF
Neuroimage Clin; 2020; 27():102302. PubMed ID: 32521474
[TBL] [Abstract][Full Text] [Related]
27. Voxel-wise correlations between cognition and cerebral blood flow using arterial spin-labeled perfusion MRI in patients with Alzheimer's disease: a cross-sectional study.
Kaneta T; Katsuse O; Hirano T; Ogawa M; Shihikura-Hino A; Yoshida K; Odawara T; Hirayasu Y; Inoue T
BMC Neurol; 2017 May; 17(1):91. PubMed ID: 28506213
[TBL] [Abstract][Full Text] [Related]
28. Clinical-pathologic correlations in vascular cognitive impairment and dementia.
Flanagan M; Larson EB; Latimer CS; Cholerton B; Crane PK; Montine KS; White LR; Keene CD; Montine TJ
Biochim Biophys Acta; 2016 May; 1862(5):945-51. PubMed ID: 26319420
[TBL] [Abstract][Full Text] [Related]
29. Quantitative Study of the Changes in Cerebral Blood Flow and Iron Deposition During Progression of Alzheimer's Disease.
Li D; Liu Y; Zeng X; Xiong Z; Yao Y; Liang D; Qu H; Xiang H; Yang Z; Nie L; Wu PY; Wang R
J Alzheimers Dis; 2020; 78(1):439-452. PubMed ID: 32986675
[TBL] [Abstract][Full Text] [Related]
30. Effect of rivastigmine on regional cerebral blood flow in Alzheimer's disease.
Cerci SS; Tamam Y; Kaya H; Yildiz M; Arslan S
Adv Ther; 2007; 24(3):611-21. PubMed ID: 17660172
[TBL] [Abstract][Full Text] [Related]
31. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
[TBL] [Abstract][Full Text] [Related]
32. Temporal gradient during famous face naming is associated with lower cerebral blood flow and gray matter volume in aging.
Hays CC; Zlatar ZZ; Campbell L; Meloy MJ; Wierenga CE
Neuropsychologia; 2017 Dec; 107():76-83. PubMed ID: 29133109
[TBL] [Abstract][Full Text] [Related]
33. Novel imaging techniques in cerebral small vessel diseases and vascular cognitive impairment.
Banerjee G; Wilson D; Jäger HR; Werring DJ
Biochim Biophys Acta; 2016 May; 1862(5):926-38. PubMed ID: 26687324
[TBL] [Abstract][Full Text] [Related]
34. Age‑ and brain region‑associated alterations of cerebral blood flow in early Alzheimer's disease assessed in AβPPSWE/PS1ΔE9 transgenic mice using arterial spin labeling.
Guo Y; Li X; Zhang M; Chen N; Wu S; Lei J; Wang Z; Wang R; Wang J; Liu H
Mol Med Rep; 2019 Apr; 19(4):3045-3052. PubMed ID: 30816468
[TBL] [Abstract][Full Text] [Related]
35. The role of insulin in the vascular contributions to age-related dementia.
Hughes TM; Craft S
Biochim Biophys Acta; 2016 May; 1862(5):983-91. PubMed ID: 26657615
[TBL] [Abstract][Full Text] [Related]
36. Cerebral white matter changes and rate of progression of dementia during cholinesterase inhibitor treatment: a retrospective cohort study.
Devine ME; Fonseca JA; Walker RW; Sikdar T; Stevens T; Walker Z
Int J Geriatr Psychiatry; 2007 Nov; 22(11):1120-6. PubMed ID: 17457951
[TBL] [Abstract][Full Text] [Related]
37. Responders to ChEI treatment of Alzheimer's disease show restitution of normal regional cortical activation.
Venneri A; McGeown WJ; Shanks MF
Curr Alzheimer Res; 2009 Apr; 6(2):97-111. PubMed ID: 19355844
[TBL] [Abstract][Full Text] [Related]
38. Functional connectivity increase in the default-mode network of patients with Alzheimer's disease after long-term treatment with Galantamine.
Blautzik J; Keeser D; Paolini M; Kirsch V; Berman A; Coates U; Reiser M; Teipel SJ; Meindl T
Eur Neuropsychopharmacol; 2016 Mar; 26(3):602-13. PubMed ID: 26796681
[TBL] [Abstract][Full Text] [Related]
39. Vascular cognitive impairment: Modeling a critical neurologic disease in vitro and in vivo.
Helman AM; Murphy MP
Biochim Biophys Acta; 2016 May; 1862(5):975-82. PubMed ID: 26704178
[TBL] [Abstract][Full Text] [Related]
40. Cerebral perfusion in the predementia stages of Alzheimer's disease.
Binnewijzend MA; Benedictus MR; Kuijer JP; van der Flier WM; Teunissen CE; Prins ND; Wattjes MP; van Berckel BN; Scheltens P; Barkhof F
Eur Radiol; 2016 Feb; 26(2):506-14. PubMed ID: 26040647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
